Journal articles on the topic 'Molecule drug delivery'
To see the other types of publications on this topic, follow the link: Molecule drug delivery.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Molecule drug delivery.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Berillo, Dmitriy, Adilkhan Yeskendir, Zharylkasyn Zharkinbekov, Kamila Raziyeva, and Arman Saparov. "Peptide-Based Drug Delivery Systems." Medicina 57, no. 11 (November 5, 2021): 1209. http://dx.doi.org/10.3390/medicina57111209.
Full textAbstract:
Peptide-based drug delivery systems have many advantages when compared to synthetic systems in that they have better biocompatibility, biochemical and biophysical properties, lack of toxicity, controlled molecular weight via solid phase synthesis and purification. Lysosomes, solid lipid nanoparticles, dendrimers, polymeric micelles can be applied by intravenous administration, however they are of artificial nature and thus may induce side effects and possess lack of ability to penetrate the blood-brain barrier. An analysis of nontoxic drug delivery systems and an establishment of prospective trends in the development of drug delivery systems was needed. This review paper summarizes data, mainly from the past 5 years, devoted to the use of peptide-based carriers for delivery of various toxic drugs, mostly anticancer or drugs with limiting bioavailability. Peptide-based drug delivery platforms are utilized as peptide–drug conjugates, injectable biodegradable particles and depots for delivering small molecule pharmaceutical substances (500 Da) and therapeutic proteins. Controlled drug delivery systems that can effectively deliver anticancer and peptide-based drugs leading to accelerated recovery without significant side effects are discussed. Moreover, cell penetrating peptides and their molecular mechanisms as targeting peptides, as well as stimuli responsive (enzyme-responsive and pH-responsive) peptides and peptide-based self-assembly scaffolds are also reviewed.
2
Jayaraman, Arthi, Christopher Price, Millicent O. Sullivan, and Kristi L. Kiick. "Collagen-Peptide-Based Drug Delivery Strategies." Technology & Innovation 21, no. 4 (December 1, 2020): 1–20. http://dx.doi.org/10.21300/21.4.2020.9.
Full textAbstract:
Collagen-targeting strategies have proven to be an effective method for targeting drugs to pathological tissues for treatment of disease. The use of collagen-like peptides for controlling the assembly of drug delivery vehicles, as well as their integration into collagen-containing matrices, offers significant advantages for tuning the morphologies of assembled structures, their thermoresponsiveness, and the loading and release of both small-molecule and macro-molecular cargo. In this contribution, we summarize the design and development of collagen-peptide-based drug delivery systems introduced by the Kiick group and detail the expansion of our understanding and the application of these unique molecules through collaborations with experts in computational simulations (Jayaraman), osteoarthritis (Price), and gene delivery (Sullivan). Kiick was inducted as a Fellow of the National Academy of Inventors in 2019 and was to deliver an address describing the innovations of her research. Given the cancellation of the NAI Annual Meeting as a result of coronavirus travel restrictions, her work based on collagen-peptide-mediated assembly is instead summarized in this contribution.
3
Wang, Ye, Yongsheng Wei, Hui Liao, Hongwei Fu, Xiaobin Yang, Qi Xiang, and Shu Zhang. "Plant Exosome-like Nanoparticles as Biological Shuttles for Transdermal Drug Delivery." Bioengineering 10, no. 1 (January 12, 2023): 104. http://dx.doi.org/10.3390/bioengineering10010104.
Full textAbstract:
Exosomes act as emerging transdermal drug delivery vehicles with high deformability and excellent permeability, which can be used to deliver various small-molecule drugs and macromolecular drugs and increase the transdermal and dermal retention of drugs, improving the local efficacy and drug delivery compliance. At present, there are many studies on the use of plant exosome-like nanoparticles (PELNVs) as drug carriers. In this review, the source, extraction, isolation, and chemical composition of plant exosomes are reviewed, and the research progress on PELNVs as drug delivery systems in transdermal drug delivery systems in recent years has elucidated the broad application prospect of PELNVs.
4
Wu, Zhi-Yuan, Cheng-Chang Lee, and Hsiu-Mei Lin. "Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function." Cancers 11, no. 5 (May 20, 2019): 697. http://dx.doi.org/10.3390/cancers11050697.
Full textAbstract:
Nanoparticle-based drug delivery systems are among the most popular research topics in recent years. Compared with traditional drug carriers, mesoporous silica nanoparticles (MSN) offer modifiable surfaces, adjustable pore sizes and good biocompatibility. Nanoparticle-based drug delivery systems have become a research direction for many scientists. With the active target factionalized, scientists could deliver drug carriers into cancer cells successfully. However, drugs in cancer cells could elicit drug resistance and induce cell exocytosis. Thus, the drug cannot be delivered to its pharmacological location, such as the nucleus. Therefore, binding the cell membrane and the nuclear target on the nanomaterial so that the anticancer drug can be delivered to its pharmacological action site is our goal. In this study, MSN-EuGd was synthesized by doping Eu3+ and Gd3+ during the synthesis of MSN. The surface of the material was then connected to the TAT peptide as the nucleus target for targeting the cancer nucleus and then loaded with the anticancer drug camptothecin (CPT). Then, the surface of MSN-EuGd was bonded to the hyaluronic acid as an active target and gatekeeper. With this system, it is possible and desirable to achieve dual imaging and dual targeting, as well as to deliver drugs to the cell nucleus under a hyaluronidase-controlled release. The experimental approach is divided into three parts. First, we conferred the material with fluorescent and magnetic dual-imaging property by doping Eu3+ and Gd3+ into the MSN. Second, modification of the cell membrane target molecule and the nucleus target molecule occurred on the surface of the nanoparticle, making the nanoparticle a target drug carrier. Third, the loading of drug molecules into the carrier gave the entire carrier a specific target profile and enabled the ability to treat cancer. In this study, we investigated the basic properties of the drug carrier, including physical properties, chemical properties, and in vitro tests. The result showed that we have successfully designed a drug delivery system that recognizes normal cells and cancer cells and has good anticancer effects.
5
Pardridge, William M. "Drug Transport across the Blood–Brain Barrier." Journal of Cerebral Blood Flow & Metabolism 32, no. 11 (August 29, 2012): 1959–72. http://dx.doi.org/10.1038/jcbfm.2012.126.
Full textAbstract:
The blood–brain barrier (BBB) prevents the brain uptake of most pharmaceuticals. This property arises from the epithelial-like tight junctions within the brain capillary endothelium. The BBB is anatomically and functionally distinct from the blood–cerebrospinal fluid barrier at the choroid plexus. Certain small molecule drugs may cross the BBB via lipid-mediated free diffusion, providing the drug has a molecular weight <400 Da and forms <8 hydrogen bonds. These chemical properties are lacking in the majority of small molecule drugs, and all large molecule drugs. Nevertheless, drugs can be reengineered for BBB transport, based on the knowledge of the endogenous transport systems within the BBB. Small molecule drugs can be synthesized that access carrier-mediated transport (CMT) systems within the BBB. Large molecule drugs can be reengineered with molecular Trojan horse delivery systems to access receptor-mediated transport (RMT) systems within the BBB. Peptide and antisense radiopharmaceuticals are made brain-penetrating with the combined use of RMT-based delivery systems and avidin–biotin technology. Knowledge on the endogenous CMT and RMT systems expressed at the BBB enable new solutions to the problem of BBB drug transport.
6
Goodman, Amanda M., Oara Neumann, Kamilla Nørregaard, Luke Henderson, Mi-Ran Choi, Susan E. Clare, and Naomi J. Halas. "Near-infrared remotely triggered drug-release strategies for cancer treatment." Proceedings of the National Academy of Sciences 114, no. 47 (November 6, 2017): 12419–24. http://dx.doi.org/10.1073/pnas.1713137114.
Full textAbstract:
Remotely controlled, localized drug delivery is highly desirable for potentially minimizing the systemic toxicity induced by the administration of typically hydrophobic chemotherapy drugs by conventional means. Nanoparticle-based drug delivery systems provide a highly promising approach for localized drug delivery, and are an emerging field of interest in cancer treatment. Here, we demonstrate near-IR light-triggered release of two drug molecules from both DNA-based and protein-based hosts that have been conjugated to near-infrared-absorbing Au nanoshells (SiO2 core, Au shell), each forming a light-responsive drug delivery complex. We show that, depending upon the drug molecule, the type of host molecule, and the laser illumination method (continuous wave or pulsed laser), in vitro light-triggered release can be achieved with both types of nanoparticle-based complexes. Two breast cancer drugs, docetaxel and HER2-targeted lapatinib, were delivered to MDA-MB-231 and SKBR3 (overexpressing HER2) breast cancer cells and compared with release in noncancerous RAW 264.7 macrophage cells. Continuous wave laser-induced release of docetaxel from a nanoshell-based DNA host complex showed increased cell death, which also coincided with nonspecific cell death from photothermal heating. Using a femtosecond pulsed laser, lapatinib release from a nanoshell-based human serum albumin protein host complex resulted in increased cancerous cell death while noncancerous control cells were unaffected. Both methods provide spatially and temporally localized drug-release strategies that can facilitate high local concentrations of chemotherapy drugs deliverable at a specific treatment site over a specific time window, with the potential for greatly minimized side effects.
7
Nordon, Galia, Aviram Magen, Ido Guy, and Kira Radinsky. "Learning to Rank Articles for Molecular Queries." Proceedings of the AAAI Conference on Artificial Intelligence 36, no. 11 (June 28, 2022): 12594–600. http://dx.doi.org/10.1609/aaai.v36i11.21532.
Full textAbstract:
The cost of developing new drugs is estimated at billions of dollars per year. Identification of new molecules for drugs involves scanning existing bio-medical literature for relevant information. As the potential drug molecule is novel, retrieval of relevant information using a simple direct search is less likely to be productive. Identifying relevant papers is therefore a more complex and challenging task, which requires searching for information on molecules with similar characteristics to the novel drug. In this paper, we present the novel task of ranking documents based on novel molecule queries. Given a chemical molecular structure, we wish to rank medical papers that will contribute to a researcher's understanding of the novel molecule drug potential. We present a set of ranking algorithms and molecular embeddings to address the task. An extensive evaluation of the algorithms is performed over the molecular embeddings, studying their performance on a benchmark retrieval corpus, which we share with the community. Additionally, we introduce a heterogeneous edge-labeled graph embedding approach to address the molecule ranking task. Our evaluation shows that the proposed embedding model can significantly improve molecule ranking methods. The system is currently deployed in a targeted drug delivery and personalized medicine research laboratory.
8
Choudhary, Yash, Abhishek Verma, Galal Mohsen Hussein Alsayadi, Pallavi Sandal, and Balak Das Kurmi. "Recent advancements in nanoparticles drug delivery systems." Pharmaspire 14, no. 02 (2022): 90–96. http://dx.doi.org/10.56933/pharmaspire.2022.14211.
Full textAbstract:
Nanoparticles in drug-delivery systems are generated by a variety of research survey. Unique physicochemical characteristics of nanostructured biomaterials include their very small and structural adaptability, high surface area to mass ratio, high reactivity, and controlled size. It enables molecularly focused cancer treatment, targeted administration of early detection of cancer lesions, early detection of cancer lesions, imaging agents, and anticancer medications, identification of tumor molecular factors by non-invasive imaging. These characteristics may be used in medicine to get around some of the drawbacks of conventional treatments. They are employed in vivo to protect the drug entity in the systemic circulation, limit drug access to the targeted areas, and deliver the drug to the site of action at a regulated and sustained pace. It reduces adverse side effects and enables more effective drug use. It must be active and therapeutically effective while in circulation and present at the target location in the right amounts. We will now go through several elements of nanoparticle formulation, the impact of their properties, characterization, and the potential of nanomedicine, improving targeted delivery of therapeutic agents, applications in drug molecule delivery, the development of novel, more powerful diagnostic and screening techniques to expand the boundaries of molecular diagnostics, and difficulties in synthesis nanoparticle platforms for dispensing various drugs.
9
Mikitsh, John L., and Ann-Marie Chacko. "Pathways for Small Molecule Delivery to the Central Nervous System across the Blood-Brain Barrier." Perspectives in Medicinal Chemistry 6 (January 2014): PMC.S13384. http://dx.doi.org/10.4137/pmc.s13384.
Full textAbstract:
The treatment of central nervous system (CNS) disease has long been difficult due to the ineffectiveness of drug delivery across the blood-brain barrier (BBB). This review summarizes important concepts of the BBB in normal versus pathophysiology and how this physical, enzymatic, and efflux barrier provides necessary protection to the CNS during drug delivery, and consequently treatment challenging. Small molecules account for the vast majority of available CNS drugs primarily due to their ability to penetrate the phospholipid membrane of the BBB by passive or carrier-mediated mechanisms. Physiochemical and biological factors relevant for designing small molecules with optimal capabilities for BBB permeability are discussed, as well as the most promising classes of transporters suitable for small-molecule drug delivery. Clinically translatable imaging methodologies for detecting and quantifying drug uptake and targeting in the brain are discussed as a means of further understanding and refining delivery parameters for both drugs and imaging probes in preclinical and clinical domains. This information can be used as a guide to design drugs with preserved drug action and better delivery profiles for improved treatment outcomes over existing therapeutic approaches.
10
Singh, Ruchita, Charles Brumlik, Mandar Vaidya, and Abhishek Choudhury. "A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery." Recent Patents on Nanotechnology 14, no. 3 (October 26, 2020): 174–92. http://dx.doi.org/10.2174/1872210514666200508121050.
Full textAbstract:
Background: Current cerebral drug delivery to the brain and Cerebrospinal Fluid (CSF) is limited by the Blood-Brain Barrier (BBB) or the blood-blood Cerebrospinal Fluid (CSF) barrier. The popular, non-invasive, intranasal delivery provides an exciting route for topical and systemic applications. For example, intranasal drug delivery of Central Nervous System (CNS) drugs can be designed to pass the BBB barrier via the nose-to-brain pathways. Recent nanotechnology research and patenting focus mainly on overcoming typical limitations including bioavailability, transport, BBB penetration, targeted delivery, controlled release rate and controlled degradation. Objective: The aim of the present study was to assess the state-of-the-art of nose-to-brain drug delivery systems and the role of nanotechnology in targeted delivery for the treatment of CNS and related therapeutic conditions. Methods: Patent and related searches were made with analytics to explore and organize nanotech work in intranasal drug delivery to the brain. Technical advancements were mapped by API, formulation and performance criteria. Patents and published patent applications were searched with concept tables of keywords, metadata (e.g., assignee) and patent classes (e.g., International Patent Classes and Cooperative Patent Classes). Results: The reviewed patents and published applications show a focus on formulations and therapeutic indications related to the nano-based nose-to-brain drug delivery. The main patented materials were surface modifiers, delivery systems and excipients. Conclusion: Surface modified nanoparticles can greatly improve drug transport and bioavailability of drugs, particularly higher molecular weight drugs. The most commonly used surface modifiers were chitosan, lectin and cyclodextrin-cross-linker complex. Nanoformulations of herbal drugs could increase drug bioavailability and reduce toxicity. Biotechnology-related drug delivery approaches such as monoclonal antibodies and genetically engineered proteins (molecular Trojan horses) deliver large molecule therapeutics.
11
Pardridge, William M. "Advanced Blood–Brain Barrier Drug Delivery." Pharmaceutics 15, no. 1 (December 27, 2022): 93. http://dx.doi.org/10.3390/pharmaceutics15010093.
Full textAbstract:
This Special Issue of Pharmaceutics, “Advanced Blood–Brain Barrier Drug Delivery,” comprises 16 articles or reviews, which cover a cross-section of brain drug delivery for either small-molecule or large-molecule therapeutics [...]
12
Rahman, Ruman, Emma Campbell, Henry Brem, Monica Pearl, Jordan Green, Miroslaw Janowski, Piotr Walczak, et al. "SCIDOT-08. CHILDREN’S BRAIN TUMOUR DRUG DELIVERY CONSORTIUM (CBTDDC)." Neuro-Oncology 21, Supplement_6 (November 2019): vi274. http://dx.doi.org/10.1093/neuonc/noz175.1149.
Full textAbstract:
Abstract INTRODUCTION The brain tumour community has seen significant progress in the discovery of new therapeutic targets and anticancer drugs. Unfortunately, advances in how to deliver drugs to the brain lag behind. The blood-brain barrier restricts the entry of many small-molecule drugs and nearly all large molecule drugs that have been developed to treat brain disorders. METHODS Following an international CNS drug delivery workshop in 2016, we were awarded funding from Children with Cancer UK to launch the Children’s Brain Tumour Drug Delivery Consortium (CBTDDC; www.cbtddc.org; @cbtddc). RESULTS The CBTDDC launched in 2017 (in Europe and the US) to raise awareness of the challenge of drug delivery in childhood brain tumours, and to initiate and strengthen research collaborations to accelerate the development of drug delivery systems. We ran a Workshop on Drug Delivery to the Brain, attracting 52 delegates from the UK, Belgium, Spain and Portugal. We liaised with UK-based funders over the drug delivery agenda, and with UK policy makers. In the US, we jointly organised the SIGN2019 meeting and we are currently liaising with the leads of Project ‘All In’ DIPG about how we can lend our support to this project. As of June 2019, 150 individuals have registered with the consortium, representing researchers, clinicians, charities, patient groups and industry. These stakeholders represent 70 research institutions, covering 15 countries (France, UK, Italy, Sweden, The Netherlands, USA, Greece, Germany, Belgium, Cuba, Denmark, Spain, Portugal, Israel and Egypt). We host a freely accessible online collaborative research database, containing the details of over 70 researchers. CONCLUSION We believe that collaboration between clinicians and multi-disciplinary researchers is vital to solving the brain tumour drug delivery challenge. We hope to raise awareness of the CBTDDC, and to extend our invitation for collaborators to join the consortium, through SCIDOT’s unrivalled drug delivery platform.
13
Javaid, Yasmeen, and Choi. "Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods." Pharmaceutics 11, no. 9 (September 1, 2019): 441. http://dx.doi.org/10.3390/pharmaceutics11090441.
Full textAbstract:
The built-in innate immunity in the human body combats various diseases and their causative agents. One of the components of this system is Toll-like receptors (TLRs), which recognize structurally conserved molecules derived from microbes and/or endogenous molecules. Nonetheless, under certain conditions, these TLRs become hypofunctional or hyperfunctional, thus leading to a disease-like condition because their normal activity is compromised. In this regard, various small-molecule drugs and recombinant therapeutic proteins have been developed to treat the relevant diseases, such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, systemic lupus erythematosus, and allergy. Some drugs for these diseases have been clinically approved; however, their efficacy can be enhanced by conventional or targeted drug delivery systems. Certain delivery vehicles such as liposomes, hydrogels, nanoparticles, dendrimers, or cyclodextrins can be employed to enhance the targeted drug delivery. This review summarizes the TLR signaling pathway, associated diseases and their treatments, and the ways to efficiently deliver the drugs to a target site.
14
Okay, Sezer. "Single-Molecule Characterization of Drug Delivery Systems." ASSAY and Drug Development Technologies 18, no. 1 (January 1, 2020): 56–63. http://dx.doi.org/10.1089/adt.2018.903.
Full text
15
Kidane, Argaw, and Padmanabh P. Bhatt. "Recent advances in small molecule drug delivery." Current Opinion in Chemical Biology 9, no. 4 (August 2005): 347–51. http://dx.doi.org/10.1016/j.cbpa.2005.06.006.
Full text
16
Tang, Lu, Jing Li, Qingqing Zhao, Ting Pan, Hui Zhong, and Wei Wang. "Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery." Pharmaceutics 13, no. 8 (July 27, 2021): 1151. http://dx.doi.org/10.3390/pharmaceutics13081151.
Full textAbstract:
The encapsulation of therapeutic agents into nano-based drug delivery system for cancer treatment has received considerable attention in recent years. Advancements in nanotechnology provide an opportunity for efficient delivery of anticancer drugs. The unique properties of nanoparticles not only allow cancer-specific drug delivery by inherent passive targeting phenomena and adopting active targeting strategies, but also improve the pharmacokinetics and bioavailability of the loaded drugs, leading to enhanced therapeutic efficacy and safety compared to conventional treatment modalities. Small molecule drugs are the most widely used anticancer agents at present, while biological macromolecules, such as therapeutic antibodies, peptides and genes, have gained increasing attention. Therefore, this review focuses on the recent achievements of novel nano-encapsulation in targeted drug delivery. A comprehensive introduction of intelligent delivery strategies based on various nanocarriers to encapsulate small molecule chemotherapeutic drugs and biological macromolecule drugs in cancer treatment will also be highlighted.
17
Sadab, Sadab, Sarad Sahu, Shubham Patel, Rubeena Khan, Basant Khare, Bhupendra Singh Thakur, Anushree Jain, and Prateek Kumar Jain. "A Comprehensive Review: Transdermal Drug Delivery System: A Tool For Novel Drug Delivery System." Asian Journal of Dental and Health Sciences 2, no. 4 (December 15, 2022): 40–47. http://dx.doi.org/10.22270/ajdhs.v2i4.24.
Full textAbstract:
In the recent decade, skin delivery (topical and transdermal) has gained an unprecedented popularity, especially due to increased incidences of chronic skin diseases, demand for targeted and patient compliant delivery and interest in life cycle management strategies among pharmaceutical companies. Transdermal drug delivery system was presented to overcome the difficulties of drug delivery especially oral route. Transdermal drug delivery refers to a means of delivering drugs through the surface of the skin for local or systemic treatment. The drug functions after absorption through the skin into the systemic circulation via capillary action at a certain rate. Transdermal patches are now widely used as cosmetic, topical and transdermal delivery systems. These patches represent a key outcome from the growth in skin science, technology and expertise developed through trial and error, clinical observation and evidence-based studies that date back to the first existing human records. A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through skin and into the bloodstream. An advantage of a transdermal drug delivery route over other types of delivery system such as oral, topical, intravenous (i.v.), intramuscular (i.m.), etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin composition offers very effective barrier that allow only small molecule based drugs to penetrate the skin and pass through the barrier. Sildenafil citrate (SLD) is a selective cyclic guanosine monophosphate-specific phosphodiesterase type 5 inhibitor used for the oral treatment of erectile dysfunction and more recently, it has been used for the treatment of pulmonary arterial hypertension and the enhancement of uteroplacental perfusion in case of fetal growth retardation. The challenges facing the oral administration of the drug include poor bioavailability and short duration of action that requires frequent administration. The main objective of transdermal drug delivery system is to deliver drugs into systemic circulation through skin at predetermined rate with minimal inter and intrapatient variations. Keyword: Skin delivery, Transdermal drug delivery, Oral rout, Sildenafil citrate, Pulmonary arterial hypertension
18
Karanjavkar, J., S. Rathod, and A. Dhumal. "Dendrimer: a novel approach for drug delivery systems." Indian Journal of Pharmaceutical and Biological Research 4, no. 03 (September 30, 2016): 39–49. http://dx.doi.org/10.30750/ijpbr.4.3.6.
Full textAbstract:
Dendrimers are hyper-branched macromolecules having tree like structure, consisting of a core molecule and alternating layers of monomers. So they can be synthesized by divergent and convergent growth methods. During synthesis, properties of dendrimers like dendrimer size, molecular mass, surface group can be controlled and configured to the desired need. Dendrimers have the ability to encapsulate and bind the guest molecule can be used for solubility enhancement, sustained release and various drug delivery applications. The reflections on biomedical and industrial applications of dendrimers given in this report clearly demonstrate the potential the class of polymer architecture and indeed substantiate the high hopes for the future of dendrimers.
19
S, Lakshmana Prabu. "A Typical Properties of Nanomaterials for Applications in Drug Delivery: A Review." Bioequivalence & Bioavailability International Journal 5, no. 2 (2021): 1–7. http://dx.doi.org/10.23880/beba-16000155.
Full textAbstract:
Developing a new drug molecule is an interdisciplinary research. A new drug molecule takes 10-14 years to develop with a 0.01% success rate. The developed new drug is administered as conventional or sustained release dosage forms. Among the conventional and sustained release dosage forms, sustained release form has many advantages. In the 21 st century, nanotechnology has become an innovative field and the nanomaterials/nanoparticles made by this technology had specific atypical properties. An extensive research interest among the researchers made a new revolution and its application almost in all the fields. This nanotechnology in medicinal profession especially in drug delivery has developed several products for the treatment and cure of many diseases. This article summarizes the different nanomaterials, its atypical properties and outlines the different methods of nanoparticle preparations for applications in drug delivery
20
Ruirui, Zhang, Jian He, Ximei Xu, Shengxian Li, Hongmei Peng, Zhiming Deng, and Yong Huang. "PLGA-based drug delivery system for combined therapy of cancer: research progress." Materials Research Express 8, no. 12 (December 1, 2021): 122002. http://dx.doi.org/10.1088/2053-1591/ac3f5e.
Full textAbstract:
Abstract In recent years, PLGA micro/nano particle drug delivery systems has been widely used in cancer treatment. According to the unique properties of PLGA, carriers of various structures are designed to keep the function of drugs or bioactive substances, ensure the effective load of molecules and improve the bioavailability of drugs in diseased parts. PLGA is one of the earliest and most commonly used biodegradable materials. It is often used for functional modification with other polymers (such as polyethylene glycol and chitosan) or other molecules (such as aptamers and ligands) to deliver various small molecule drugs (such as DOX and DTX) and bioactive macromolecules (such as proteins and nucleic acids) to improve targeting, controlled release and therapeutic properties. In this paper, the preparation methods, physical and chemical properties and medical applications of PLGA micro/nano particles are discussed. We focused on the recent research progress of the PLGA-based drug carrier system in tumor combination therapy.
21
Chung, Shei Li, Maxine Swee-Li Yee, Ling-Wei Hii, Wei-Meng Lim, Mui Yen Ho, Poi Sim Khiew, and Chee-Onn Leong. "Advances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment." Nanomaterials 11, no. 10 (September 22, 2021): 2467. http://dx.doi.org/10.3390/nano11102467.
Full textAbstract:
Recent advancements in nanotechnology have improved our understanding of cancer treatment and allowed the opportunity to develop novel delivery systems for cancer therapy. The biological complexities of cancer and tumour micro-environments have been shown to be highly challenging when treated with a single therapeutic approach. Current co-delivery systems which involve delivering small molecule drugs and short-interfering RNA (siRNA) have demonstrated the potential of effective suppression of tumour growth. It is worth noting that a considerable number of studies have demonstrated the synergistic effect of co-delivery systems combining siRNA and small molecule drugs, with promising results when compared to single-drug approaches. This review focuses on the recent advances in co-delivery of siRNA and small molecule drugs. The co-delivery systems are categorized based on the material classes of drug carriers. We discuss the critical properties of materials that enable co-delivery of two distinct anti-tumour agents with different properties. Key examples of co-delivery of drug/siRNA from the recent literature are highlighted and discussed. We summarize the current and emerging issues in this rapidly changing field of research in biomaterials for cancer treatments.
22
Wang, Siteng, Hongping Deng, Ping Huang, Pei Sun, Xiaohua Huang, Yue Su, Xinyuan Zhu, Jian Shen, and Deyue Yan. "Real-time self-tracking of an anticancer small molecule nanodrug based on colorful fluorescence variations." RSC Advances 6, no. 15 (2016): 12472–78. http://dx.doi.org/10.1039/c5ra24273h.
Full text
23
Sah, Shailendra Kumar, Ashutosh Badola, and Bipin Kumar Nayak. "Emulgel: Magnifying the application of topical drug delivery." Indian Journal of Pharmaceutical and Biological Research 5, no. 01 (January 31, 2017): 25–33. http://dx.doi.org/10.30750/ijpbr.5.1.4.
Full textAbstract:
Topical drug delivery is mostly culled for the local dermatological action, but recently the new technologies are also enhancing its systemic effect. They are generally applied for the purpose as antiseptics, antifungal agents, skin emollients, and protectants. The activity of topical preparation confide in the various factors as drug solubility, its lipophilicity, contact time to skin, its permeability. Many widely used topical agents like ointments, creams, lotions, gel are associated with disadvantages like stability problems, stickiness and lesser spreading coefficient, irritation, allergic reactions, poor permeability, poor absorption and difficulty in absorption of large molecule, to rectify this the new concept of Emulgel has been introduced with the main objective to deliver hydrophobic drug molecule. Emulgel is oil in water or water in oil emulsion carrying drug to be incorporated in gel base to obtain gellified emulsion. Emulgel shows the controlled and better release effect of drug by virtue of combined effect of gel and emulsion with increased stability. Gel having various advantages as non greasy and favors good patient compliance in field of cosmetology and dermatology but are still limited to the deliver hydrophobic drugs. So the Emulgel comes to favour the hydrophobic drugs to give the advantages of gel. Emulgels have several advantages in the field of dermatology such as being thixotropic, greaseless, easily spreadable, easily removable, emollient, nonstaining, long shelf life, bio-friendly, transparent and pleasing appearance. Factors such as gelling agent, oil agent, emulsifiers influence the stability and efficacy of emulgel. So emulgels can be the better semisolid preparation than other conventional systems. At present the emulgel are being used for the delivery of analgesics, anti-inflammatory, anti-fungal, anti-acne drugs and various cosmetic formulations with still wide range to explore.
24
Liu, Fei, Yuan Sun, Chen Kang, and Hongyan Zhu. "Pegylated Drug Delivery Systems: From Design to Biomedical Applications." Nano LIFE 06, no. 03n04 (October 18, 2016): 1642002. http://dx.doi.org/10.1142/s1793984416420022.
Full textAbstract:
Pegylation, as a simple procedure to attach hydrophilic polyethylene glycol (PEG) onto therapeutic molecule or drug carriers has been utilized widely to deliver small molecules, proteins and peptides. It was first reported in 1970s by Dr. Frank Davis of Rutgers University and Dr. Abuchowsky in the studies of PEG modified albumin and catalase. The significance of this method at that time was able to successfully modify the enzyme with better hydrophilicity but also keep the enzymatic activity. The employment of PEG has provided superior stability of drug delivery systems (DDS) and enhanced the circulation time in vivo. Simple conjugation of PEG chains with various molecular weights enables the possibility to regulate the properties of desired DDS and led to important contribution in targeting therapy and diagnosis. Pegylation has been reported to be able to protect peptides by shielding antigenic epitopes from reticuloendothelial (RES) clearance and avoid enzymes being recognized by immune system and avoid early degradation. In addition, utilization of PEG in DDS are reported with enhanced delivery efficiency, prolonged circulation time and improved stability, especially active enzymes and peptides drug delivery. In this paper, we will conclude current studies about Pegylated DDS and their biomedical applications from both in vitro and in vivo studies.
25
Choi, Moonhyun, Arman Moini Jazani, Jung Kwon Oh, and Seung Man Noh. "Perfluorocarbon Nanodroplets for Dual Delivery with Ultrasound/GSH-Responsive Release of Model Drug and Passive Release of Nitric Oxide." Polymers 14, no. 11 (May 31, 2022): 2240. http://dx.doi.org/10.3390/polym14112240.
Full textAbstract:
Nitric oxide (NO) plays a critical role as an important signaling molecule for a variety of biological functions, particularly inhibiting cell proliferation or killing target pathogens. To deliver active radical NO gaseous molecule whose half-life is a few seconds in a stable state, the design and development of effective exogenous NO supply nanocarriers are essential. Additionally, the delivery of desired drugs with NO can produce synergistic effects. Herein, we report a new approach that allows for the fabrication of dual ultrasound (US)/glutathione (GSH)-responsive perfluorocarbon (PFC) nanodroplets for the controlled release of model drug and passive release of safely incorporated NO. The approach centers on the synthesis of a disulfide-labeled amphiphilic block copolymer and its use as a GSH-degradable macromolecular emulsifier for oil-in-water emulsification process of PFC. The fabricated PFC nanodroplets are colloidally stable and enable the encapsulation of both NO and model drugs. Encapsulated drug molecules are synergistically released when ultrasound and GSH are presented, while NO molecules are passively but rapidly released. Our preliminary results demonstrate that the approach is versatile and can be extended to not only GSH-responsive but also other stimuli-responsive block copolymers, thereby allowing for the fabrication of broad choices of stimuli-responsive (smart) PFC-nanodroplets in aqueous solution for dual delivery of drug and NO therapeutics.
26
Suravajhala, Renuka, Harshavardhan Reddy Burri, and Babita Malik. "Selective Targeted Drug Delivery Mechanism via Molecular Imprinted Polymers in Cancer Therapeutics." Current Topics in Medicinal Chemistry 20, no. 22 (October 8, 2020): 1993–98. http://dx.doi.org/10.2174/1568026620666200622150710.
Full textAbstract:
Artificial receptor-like structures such as molecular imprinted polymers (MIPs) are biomimetic molecules are used to replicate target specific antibody-antigen mechanism. In MIPs, selective binding of template molecule can be significantly correlated with lock and key mechanism, which play a major role in the drug delivery mechanism. The MIPs are biocompatible with high efficiency and are considered in several drug delivery and biosensor applications besides continuous and controlled drug release leading to better therapeutics. There is a need to explore the potential synthetic methods to improve MIPs with respect to the imprinting capacity in cancer therapeutics. In this review, we focus on MIPs as drug delivery mechanism in cancer and the challenges related to their synthesis and applications.
27
Kumar, Abhishek, and Meenakshi Bharkatiya. "A Recent Update on Formulation and Development of Gastro-Retentive Drug Delivery Systems." International Journal of Pharmaceutical Sciences and Nanotechnology 14, no. 1 (January 1, 2021): 5257–70. http://dx.doi.org/10.37285/ijpsn.2021.14.1.1.
Full textAbstract:
Oral route has been the most convenient and accepted route of drug delivery. Owing to tremendous curative benefits of the oral controlled release dosage forms are being preferred as the interesting topic in pharmaceutical field to achieved improved therapeutics advantages. Gastro retentive drug delivery system is novel drug delivery systems which has an upper hand owing to its ability of prolonged retaining ability in the stomach and thereby increase gastric residence time of drugs and also improves bioavailability of drugs. Concept of novel drug delivery system arose to overcome the certain aspect related to physicochemical properties of drug molecule and the related formulations. In this context, various gastro retentive drug delivery systems have been used to improve the therapeutic efficacy of drugs that have a narrow absorption window, are unstable at alkaline pH, are soluble in acidic conditions, and are active locally in the stomach. Concept of novel drug delivery system arose to overcome the certain aspect related to physicochemical properties of drug molecule and the related formulations. Various approaches are currently used including gastro retentive floating drug delivery systems, swelling and expanding system, polymeric bio adhesive systems, modified shape systems, high density system and other delayed gastric emptying devices. Moreover, future perspectives on this technology are discussed to minimize the gastric emptying rate in both the fasted and fed states. The present review briefly addresses the physiology of the gastric emptying process with respect to floating drug delivery systems. The purpose of this review is to bring together the recent literature with respect to the method of preparation, and various parameters affecting the performance and characterization of floating microspheres. Attempt has been made to summarize important factors controlling gastro retentive drug delivery systems. Overall, this review may inform and guide formulation scientists in designing the gastro retentive drug delivery system.
28
Pant, Shailaja, Ashutosh Badola, and Preeti Kothiyal. "A review on gastroretentive drug delivery system." Indian Journal of Pharmaceutical and Biological Research 4, no. 2 (June 30, 2016): 01–10. http://dx.doi.org/10.30750/ijpbr.4.2.1.
Full textAbstract:
Oral controlled release and site specific drug delivery system has been of great interest in pharmaceutical field to achieve improved therapeutic advantage. Concept of novel drug delivery system arose to overcome certain aspect related to physicochemical properties of drug molecule and the related formulations. Gastro retentive drug delivery system is one of such novel approaches to prolong gastric residence time, thereby targeting site specific drug release in the stomach for local or systemic effects. This approach is useful particularly for the drugs which have narrow absorption window in the upper part of gastro intestinal tract. In this review we have been discussed various approaches of gastro retentive drug delivery system, such as floating and non-floating systems.
29
Wang, Qian, Nan Jiang, Bo Fu, Fan Huang, and Jianfeng Liu. "Self-assembling peptide-based nanodrug delivery systems." Biomaterials Science 7, no. 12 (2019): 4888–911. http://dx.doi.org/10.1039/c9bm01212e.
Full textAbstract:
The present review outlines the methods designing self-assembling peptide-based NDDs for small molecule drugs, with an emphasis on the different drug delivery strategies and their applications in using peptides and peptide conjugates.
30
Supraja, Bommala, and Saritha Mulangi. "An updated review on pharmacosomes, a vesicular drug delivery system." Journal of Drug Delivery and Therapeutics 9, no. 1-s (February 15, 2019): 393–402. http://dx.doi.org/10.22270/jddt.v9i1-s.2234.
Full textAbstract:
Novel drug delivery system mainly consents about achieving the targeted concentration to release the drug at targeted site by using carrier system, altering the structure and microenvironment around the drug. Especially drugs which are having narrow therapeutic window are difficult to formulate, with the advantage of novel drug delivery systems like particulate, polymeric carrier, macromolecular and cellular carriers. They are used to reduce complications as well as release the drug in a determined fusion at targeted site. In vesicular drug delivery system drug binds covalently to the lipid molecule by which the drug release is in a controlled manner and also drugs which are of hydrophilic or lipophilic nature can be delivered by using vesicular drug delivery systems. The release of drug from the vesicles depends on the physicochemical properties of both the drug and carrier. Vesicular drug delivery includes liposomes, niososmes, transferosomes, pharmacosomes, electrosomes, ethosomes etc. Of all these drug delivery systems pharmacosomes are having more advantages like no leakage or loss of drug, stability, high entrapment efficiency etc, pharmacosomes may be hexagonal aggregates , ultrafine vesicular and micellar forms. Both synthetic and natural drugs which are facing difficulties like low solubility and low permeability can be effectively formulated and can achieve required pharmacokinetic and pharmacodynamic parameters. Pharmacosomes are prepared by hand shaking method, ether injection, solvent evaporation method, anhydrous co-solvent lyophilyzation, supercritical fluid approach and other alternative methods they are characterized by complex determination, surface morphology, drug entrapment, solubility, drug lipid compatibility, crystal state measurement, dissolution studies and in vitro drug release rate.
Keywords: Pharmacosomes, covalently, vesicular drug delivery system, hexagonal aggregates, micellar, ultrafine.
31
Brenner, Jacob S., Raisa Yu Kiseleva, Patrick M. Glassman, Hamideh Parhiz, Colin F. Greineder, Elizabeth D. Hood, Vladimir V. Shuvaev, and Vladimir R. Muzykantov. "The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series)." Pulmonary Circulation 8, no. 1 (December 20, 2017): 204589321775232. http://dx.doi.org/10.1177/2045893217752329.
Full textAbstract:
The pulmonary vasculature plays an important role in many lung pathologies, such as pulmonary arterial hypertension, primary graft dysfunction of lung transplant, and acute respiratory distress syndrome. Therapy for these diseases is quite limited, largely due to dose-limiting side effects of numerous drugs that have been trialed or approved. High doses of drugs targeting the pulmonary vasculature are needed due to the lack of specific affinity of therapeutic compounds to the vasculature. To overcome this problem, the field of targeted drug delivery aims to target drugs to the pulmonary endothelial cells, especially those in pathological regions. The field uses a variety of drug delivery systems (DDSs), ranging from nano-scale drug carriers, such as liposomes, to methods of conjugating drugs to affinity moieites, such as antibodies. These DDSs can deliver small molecule drugs, protein therapeutics, and imaging agents. Here we review targeted drug delivery to the pulmonary endothelium for the treatment of pulmonary diseases. Cautionary notes are made of the risk–benefit ratio and safety—parameters one should keep in mind when developing a translational therapeutic.
32
Zheng, Haoquan, Cheuk-Wai Tai, Jie Su, Xiaodong Zou, and Feifei Gao. "Ultra-small mesoporous silica nanoparticles as efficient carriers for pH responsive releases of anti-cancer drugs." Dalton Transactions 44, no. 46 (2015): 20186–92. http://dx.doi.org/10.1039/c5dt03700j.
Full textAbstract:
A pH-responsive drug delivery system via mesoporous silica nanoparticles as carriers can be achieved based on electrostatic interactions between drug molecules and carriers, when the isoelectric point of the drug molecule is high.
33
Sandoval-Yañez, Claudia, and Cristian Castro Rodriguez. "Dendrimers: Amazing Platforms for Bioactive Molecule Delivery Systems." Materials 13, no. 3 (January 24, 2020): 570. http://dx.doi.org/10.3390/ma13030570.
Full textAbstract:
Today, dendrimers are the main nanoparticle applied to drug delivery systems. The physicochemical characteristics of dendrimers and their versatility structural modification make them attractive to applied as a platform to bioactive molecules transport. Nanoformulations based on dendrimers enhance low solubility drugs, arrival to the target tissue, drugs bioavailability, and controlled release. This review describes the latter approaches on the transport of bioactive molecules based on dendrimers. The review focus is on the last therapeutic strategies addressed by dendrimers conjugated with bioactive molecules. A brief review of the latest studies in therapies against cancer and cardiovascular diseases, as well as future projections in the area, are addressed.
34
Patel, Manish P., Ravi R. Patel, and Jayvadan K. Patel. "Chitosan Mediated Targeted Drug Delivery System: A Review." Journal of Pharmacy & Pharmaceutical Sciences 13, no. 4 (November 16, 2010): 536. http://dx.doi.org/10.18433/j3jc7c.
Full textAbstract:
Chitosan has prompted the continuous movement for the development of safe and effective drug delivery systems because of its unique physicochemical and biological characteristics. The primary hydroxyl and amine groups located on the backbone of chitosan allow for chemical modification to control its physical properties. When the hydrophobic moiety is conjugated to a chitosan molecule, the resulting amphiphile may form self-assembled nanoparticles that can encapsulate a quantity of drugs and deliver them to a specific site of action. Chemical attachment of the drug to the chitosan throughout the functional linker may produce useful prodrugs, exhibiting the appropriate biological activity at the target site. Mucoadhesive and absorption enhancement properties of chitosan increase the in vivo residence time of the dosage form in the gastrointestinal tract and improve the bioavailability of various drugs. The main objective of this review is to provide an insight into various target-specific carriers, based on chitosan and its derivatives. The first part of the review is concerned with the organ-specific delivery system using chitosan and its derivatives. The subsequent section considers the recent developments of drug delivery carriers for cancer therapy with special focus on various targeting strategies.
35
Jain, Sameeksha, Meena Kirar, Mahima Bindeliya, Lucky Sen, Madhur Soni, Md Shan, Arpana Purohit, and Prateek Kumar Jain. "Novel Drug Delivery Systems: An Overview." Asian Journal of Dental and Health Sciences 2, no. 1 (March 15, 2022): 33–39. http://dx.doi.org/10.22270/ajdhs.v2i1.14.
Full textAbstract:
The performance of an existing medicinal molecule in terms of patient compliance, safety, and efficacy can be greatly enhanced by evolving it from a traditional form to a unique delivery mechanism. An old medication molecule can be given new life as a Novel Drug Delivery System. The limitations of the conventional drug delivery methods are addressed by the innovative drug delivery system, which is a novel method of drug administration. A significant improvement in the ability to release a drug at a specified spot and rate is possible with a novel drug delivery system that is properly developed. Pharmaceutical companies are working to create novel drug delivery systems in order to give medications to patients effectively and with fewer side effects. The fundamentals of novel drug delivery systems, as well as their various varieties, are covered in this article. The scientific requirements to be incorporated in novel drug delivery systems, such as nanoparticles, microemulsions, matrix systems, solid dispersions, liposomes, solid lipid nanoparticles, and so on, can be met by modern phytopharmaceuticals research, though, by determining pharmacokinetics, mechanism of action, site of action, required precise dose, etc.
Keywords: Novel drug delivery system, Conventional drug delivery, Pharmaceutical companies, Pharmacokinetics.
36
Roberts, Lynne, and Daniel Smith. "Targeting toxins!: Drug delivery with poisons." Biochemist 24, no. 1 (February 1, 2002): 18–20. http://dx.doi.org/10.1042/bio02401018.
Full textAbstract:
Many organisms produce potently toxic proteins that act on other cells, sometimes with lethal effects. In this way, such proteins help to increase the chance of survival or proliferation of the producing organism. Moreover, a lot of toxins have an exquisitely specific action. For example, proteins studied in the Warwick toxin laboratory -- ricin, a toxin from the castor oil seed (Figure 1), and its relatives from the pathogenic Escherichia coli 0157 and the dysentery-causing bacterium (Shigella dysenteriae), have evolved to selectively target ribosomes within the cells of susceptible organisms, thereby enabling a fatal disruption of protein synthesis. What is very striking is the clever way these particular toxins exploit intracellular transport pathways to travel from the cell surface to their substrates in the cytosol. Once delivered there, each toxin molecule can disable approximately 2000 polysomes per minute, enough to eventually kill the cell. Research is now aimed at elucidating the molecular details of the cellular uptake of ricin and the Shiga family of toxins, and of exploiting their unusual trafficking properties for biotechnological purposes.
37
Briggs, Francesca, Daryn Browne, and Prashanth Asuri. "Role of Polymer Concentration and Crosslinking Density on Release Rates of Small Molecule Drugs." International Journal of Molecular Sciences 23, no. 8 (April 8, 2022): 4118. http://dx.doi.org/10.3390/ijms23084118.
Full textAbstract:
Over the past few years, researchers have demonstrated the use of hydrogels to design drug delivery platforms that offer a variety of benefits, including but not limited to longer circulation times, reduced drug degradation, and improved targeting. Furthermore, a variety of strategies have been explored to develop stimulus-responsive hydrogels to design smart drug delivery platforms that can release drugs to specific target areas and at predetermined rates. However, only a few studies have focused on exploring how innate hydrogel properties can be optimized and modulated to tailor drug dosage and release rates. Here, we investigated the individual and combined roles of polymer concentration and crosslinking density (controlled using both chemical and nanoparticle-mediated physical crosslinking) on drug delivery rates. These experiments indicated a strong correlation between the aforementioned hydrogel properties and drug release rates. Importantly, they also revealed the existence of a saturation point in the ability to control drug release rates through a combination of chemical and physical crosslinkers. Collectively, our analyses describe how different hydrogel properties affect drug release rates and lay the foundation to develop drug delivery platforms that can be programmed to release a variety of bioactive payloads at defined rates.
38
Kaur, Veerpal, Amandeep Singh Amandeep Singh, Kirandeep Kaur, and Goutam Rath. "Targeted Based Drug Delivery System for Colon Cancer." Journal of Drug Delivery and Therapeutics 10, no. 1 (January 15, 2020): 111–22. http://dx.doi.org/10.22270/jddt.v10i1.3831.
Full textAbstract:
Regardless of so many advancements in the treatment, colon cancer still stands third in cancer-related deaths worldwide. Toxicity associated with conventional drugs is one of the major problems associated with chemotherapy. Targeted delivery works by concentrating the medication in the tissues of interest and reducing the concentration in remaining tissues. This delivery system helps the drug molecule to reach preferably to the desired site. The targeting will lower the requirement of a higher dose of the drug thus reducing the dosage frequency. The present review focuses on the various parameters of targeted drug delivery including the criteria for selection of drug and factors affecting the targeted drug delivery and also includes the brief discussion about different targeted drug deliveries for colon cancer therapies.
Keywords: colon cancer, targeted drug delivery, chemotherapies
39
Yu, Han, Na Ning, Xi Meng, Chuda Chittasupho, Lingling Jiang, and Yunqi Zhao. "Sequential Drug Delivery in Targeted Cancer Therapy." Pharmaceutics 14, no. 3 (March 5, 2022): 573. http://dx.doi.org/10.3390/pharmaceutics14030573.
Full textAbstract:
Cancer is a major public health problem and one of the leading causes of death. However, traditional cancer therapy may damage normal cells and cause side effects. Many targeted drug delivery platforms have been developed to overcome the limitations of the free form of therapeutics and biological barriers. The commonly used cancer cell surface targets are CD44, matrix metalloproteinase-2, folate receptors, etc. Once the drug enters the cell, active delivery of the drug molecule to its final destination is still preferred. The subcellular targeting strategies include using glucocorticoid receptors for nuclear targeting, negative mitochondrial membrane potential and N-acetylgalactosaminyltransferase for Golgi apparatus targeting, etc. Therefore, the most effective way to deliver therapeutic agents is through a sequential drug delivery system that simultaneously achieves cellular- and subcellular-level targeting. The dual-targeting delivery holds great promise for improving therapeutic effects and overcoming drug resistance. This review classifies sequential drug delivery systems based on final targeted organelles. We summarize different targeting strategies and mechanisms and gave examples of each case.
40
Wan, Chen-rei, Leroy Muya, Viral Kansara, and Thomas A. Ciulla. "Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases." Pharmaceutics 13, no. 2 (February 22, 2021): 288. http://dx.doi.org/10.3390/pharmaceutics13020288.
Full textAbstract:
Suprachoroidal drug delivery technology has advanced rapidly and emerged as a promising administration route for a variety of therapeutic candidates, in order to target multiple ocular diseases, ranging from neovascular age-related macular degeneration to choroidal melanoma. This review summarizes the latest preclinical and clinical progress in suprachoroidal delivery of therapeutic agents, including small molecule suspensions, polymeric entrapped small molecules, gene therapy (viral and nonviral nanoparticles), viral nanoparticle conjugates (VNCs), and cell therapy. Formulation customization is critical in achieving favorable pharmacokinetics, and sustained drug release profiles have been repeatedly observed for multiple small molecule suspensions and polymeric formulations. Novel therapeutic agents such as viral and nonviral gene therapy, as well as VNCs, have demonstrated promise in animal studies. Several of these suprachoroidally-administered therapies have been assessed in clinical trials, including small molecule suspensions of triamcinolone acetonide and axitinib, viral vector RGX-314 for gene therapy, and VNC AU-011. With continued drug delivery research and optimization, coupled with customized drug formulations, suprachoroidal drug delivery may address large unmet therapeutic needs in ophthalmology, targeting affected tissues with novel therapies for efficacy benefits, compartmentalizing therapies away from unaffected tissues for safety benefits, and achieving durability to relieve the treatment burden noted with current agents.
41
Mohd Muaz Mughees, Mughees Ahmad Ansari, Afifa Mughees, Faisal Farooque, and Mohd Wasi. "Virosomes as drug delivery system: An updated review." International Journal of Research in Pharmaceutical Sciences 12, no. 3 (September 15, 2021): 2239–47. http://dx.doi.org/10.26452/ijrps.v12i3.4850.
Full textAbstract:
Amid the era of development in all sphere of Biotechnology, Biochemistry and Pharmacology, it would not be an exaggeration to say that we have a myriad of molecules available to us in labs with promising results against many diseases. The limitation lies in the fact that some molecules are toxic when they act on organs other than their targets. Yet others cannot reach their targets in the desired concentration, be it due to easy degradation in the gut or high first-pass metabolism or very short half-life, etc. Thus, to overcome this, we have an alternate drug delivery system, namely Virosomes. The purpose of this review is to understand the drug delivery aspect of the virosomes, its type, structure, method of preparation, mechanism of action, administration routes and the application in the medical field. Virosomes are the regenerated viral envelope having a central empty space that can act as the vehicles for drug delivery. The central empty space can be filled with the desired bioactive molecule. Virosomes are most commonly prepared by using the reconstituted viral envelope of the Influenza virus, but other virus such as Sendai or HVJ, Hepatitis B Virus, HIV, New castle Disease Virus etc., can also be used for the preparation of virosomes. Virosomes has a great potential as the drug delivery system for almost all types of the drugs, and this encourages the researchers and therapeutic industries to enhance their pharmacological profiles, clinical result and stability.
42
AZIZI, ALI, and SADOLLAH EBRAHIMI. "MOLECULAR DYNAMICS STUDY OF PTX ADSORPTION ONTO N-DOPED GRAPHENE IN VACUUM AND AQUEOUS ENVIRONMENTS." Nano 09, no. 08 (December 2014): 1450088. http://dx.doi.org/10.1142/s179329201450088x.
Full textAbstract:
In this study, the adsorption of Paclitaxel (PTX) drug molecule onto graphene doped with nitrogen atoms ( N -doped graphene) in vacuum and aqueous environments has been investigated. To do this, we have employed a series of very accurate molecular dynamics (MD) simulations to reveal the effect of N atoms concentration on drug molecule adsorption. The critical value of N adatoms is obtained. The water concentration, adsorption energy, and average distance of drug molecule from surface are calculated. Overall, our findings provide crucial information for the performance of N -doped graphene in drug delivery.
43
Kumar, Sahil, Bandna Sharma, Kiran Thakur, Tilak R. Bhardwaj, Deo N. Prasad, and Rajesh K. Singh. "Recent Advances in the Development of Polymeric Nanocarrier Formulations for the Treatment of Colon Cancer." Drug Delivery Letters 9, no. 1 (February 6, 2019): 2–14. http://dx.doi.org/10.2174/2210303108666181109120710.
Full textAbstract:
Background: Many efforts have been explored in the last decade to treat colon cancer but nanoparticulate drug delivery systems are making a vital contribution in the improvement of drug delivery to colon cancer cells. Objective: In this review, we attempt to highlight recent advancements in the development of novel drug delivery systems of nanoparticles for the targeted drug delivery to colon. Polymers like Epithelial Cell Adhesion Molecule (EpCAM) aptamer chitosan, Hyaluronic Acid (HA), Chitosan (CS)– Carboxymethyl Starch (CMS), silsesquioxane capped mesoporous silica, Near IR (NIR) fluorescent Human Serum Albumin (HAS), poly(ethylene glycol)-conjugated hyaluronic acid etc. have been discussed by employing various anticancer drugs like doxorubicin, oxaliplatin, paclitaxel, 5-fluorouracil etc. Conclusion: These novel drug delivery systems have been determined to be more efficacious in terms of stability, sustained and targeted drug delivery, therapeutic efficacy, improved bioavailability and enhanced anticancer activity.
44
Zhong, Tian, Ran Huang, and Lianjiang Tan. "Amphiphilic drug–drug assembly via dual-responsive linkages for small-molecule anticancer drug delivery." RSC Advances 6, no. 71 (2016): 66420–30. http://dx.doi.org/10.1039/c6ra15675d.
Full textAbstract:
Amphiphilic drug–drug assembly nanoparticles based on dual-responsive H-bonding-instructed disulfide bonds can release irinotecan and doxorubicin simultaneously in cancer cells for anticancer purposes.
45
Honari, Arvin, Darrah A. Merillat, Aditi Bellary, Mohammadaref Ghaderi, and Shashank R. Sirsi. "Improving Release of Liposome-Encapsulated Drugs with Focused Ultrasound and Vaporizable Droplet-Liposome Nanoclusters." Pharmaceutics 13, no. 5 (April 22, 2021): 609. http://dx.doi.org/10.3390/pharmaceutics13050609.
Full textAbstract:
Active targeted delivery of small molecule drugs is becoming increasingly important in personalized therapies, especially in cancer, brain disorders, and a wide variety of other diseases. However, effective means of spatial targeting and delivering high drug payloads in vivo are still lacking. Focused ultrasound combined with superheated phase-shift nanodroplets, which vaporize into microbubbles using heat and sound, are rapidly becoming a popular strategy for targeted drug delivery. Focused ultrasound can target deep tissue with excellent spatial precision and without using ionizing energy, thus can activate nanodroplets in circulation. One of the main limitations of this technology has been poor drug loading in the droplet core or the shell material. To address this need, we have developed a strategy to combine low-boiling point decafluorabutane and octafluoropropane (DFB and OFP) nanodroplets with drug-loaded liposomes, creating phase-changeable droplet-liposome clusters (PDLCs). We demonstrate a facile method of assembling submicron PDLCs with high drug-loading capacity on the droplet surface. Furthermore, we demonstrate that chemical tethering of liposomes in PDLCs enables a rapid release of their encapsulated cargo upon acoustic activation (>60% using OFP-based PDLCs). Rapid uncaging of small molecule drugs would make them immediately bioavailable in target tissue or promote better penetration in local tissue following intravascular release. PDLCs developed in this study can be used to deliver a wide variety of liposome-encapsulated therapeutics or imaging agents for multi-modal imaging applications. We also outline a strategy to deliver a surrogate encapsulated drug, fluorescein, to tumors in vivo using focused ultrasound energy and PDLCs.
46
Tomeh, Mhd Anas, Roja Hadianamrei, and Xiubo Zhao. "Silk Fibroin as a Functional Biomaterial for Drug and Gene Delivery." Pharmaceutics 11, no. 10 (September 26, 2019): 494. http://dx.doi.org/10.3390/pharmaceutics11100494.
Full textAbstract:
Silk is a natural polymer with unique physicochemical and mechanical properties which makes it a desirable biomaterial for biomedical and pharmaceutical applications. Silk fibroin (SF) has been widely used for preparation of drug delivery systems due to its biocompatibility, controllable degradability and tunable drug release properties. SF-based drug delivery systems can encapsulate and stabilize various small molecule drugs as well as large biological drugs such as proteins and DNA to enhance their shelf lives and control the release to enhance their circulation time in the blood and thus the duration of action. Understanding the properties of SF and the potential ways of manipulating its structure to modify its physicochemical and mechanical properties allows for preparation of modulated drug delivery systems with desirable efficacies. This review will discuss the properties of SF material and summarize the recent advances of SF-based drug and gene delivery systems. Furthermore, conjugation of the SF to other biomolecules or polymers for tissue-specific drug delivery will also be discussed.
47
Wang, Peng, Ge Yan, Xiaodong Zhu, Yingying Du, Da Chen, and Jinjuan Zhang. "Heterofullerene MC59 (M = B, Si, Al) as Potential Carriers for Hydroxyurea Drug Delivery." Nanomaterials 11, no. 1 (January 7, 2021): 115. http://dx.doi.org/10.3390/nano11010115.
Full textAbstract:
As a representative nanomaterial, C60 and its derivatives have drawn much attention in the field of drug delivery over the past years, due to their unique geometric and electronic structures. Herein, the interactions of hydroxyurea (HU) drug with the pristine C60 and heterofullerene MC59 (M = B, Si, Al) were investigated using the density functional theory calculations. The geometric and electronic properties in terms of adsorption configuration, adsorption energy, Hirshfeld charge, frontier molecular orbitals, and charge density difference are calculated. In contrast to pristine C60, it is found that HU molecule is chemisorbed on the BC59, SiC59, and AlC59 molecules with moderate adsorption energy and apparent charge transfer. Therefore, heterofullerene BC59, SiC59, and AlC59 are expected to be promising carriers for hydroxyurea drug delivery.
48
Wang, Peng, Ge Yan, Xiaodong Zhu, Yingying Du, Da Chen, and Jinjuan Zhang. "Heterofullerene MC59 (M = B, Si, Al) as Potential Carriers for Hydroxyurea Drug Delivery." Nanomaterials 11, no. 1 (January 7, 2021): 115. http://dx.doi.org/10.3390/nano11010115.
Full textAbstract:
As a representative nanomaterial, C60 and its derivatives have drawn much attention in the field of drug delivery over the past years, due to their unique geometric and electronic structures. Herein, the interactions of hydroxyurea (HU) drug with the pristine C60 and heterofullerene MC59 (M = B, Si, Al) were investigated using the density functional theory calculations. The geometric and electronic properties in terms of adsorption configuration, adsorption energy, Hirshfeld charge, frontier molecular orbitals, and charge density difference are calculated. In contrast to pristine C60, it is found that HU molecule is chemisorbed on the BC59, SiC59, and AlC59 molecules with moderate adsorption energy and apparent charge transfer. Therefore, heterofullerene BC59, SiC59, and AlC59 are expected to be promising carriers for hydroxyurea drug delivery.
49
Coentro, João Q., Alessia di Nubila, Ulrike May, Stuart Prince, John Zwaagstra, Tero A. H. Järvinen, and Dimitrios I. Zeugolis. "Dual drug delivery collagen vehicles for modulation of skin fibrosis in vitro." Biomedical Materials 17, no. 2 (March 1, 2022): 025017. http://dx.doi.org/10.1088/1748-605x/ac5673.
Full textAbstract:
Abstract Single molecule drug delivery systems have failed to yield functional therapeutic outcomes, triggering investigations into multi-molecular drug delivery vehicles. In the context of skin fibrosis, although multi-drug systems have been assessed, no system has assessed molecular combinations that directly and specifically reduce cell proliferation, collagen synthesis and transforming growth factor β1 (TGFβ1) expression. Herein, a core–shell collagen type I hydrogel system was developed for the dual delivery of a TGFβ trap, a soluble recombinant protein that inhibits TGFβ signalling, and Trichostatin A (TSA), a small molecule inhibitor of histone deacetylases. The antifibrotic potential of the dual delivery system was assessed in an in vitro skin fibrosis model induced by macromolecular crowding (MMC) and TGFβ1. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and high performance liquid chromatography analyses revealed that ∼50% of the TGFβ trap and ∼30% of the TSA were released from the core and shell compartments, respectively, of the hydrogel system after 10 d (longest time point assessed) in culture. As a direct consequence of this slow release, the core (TGFβ trap)/shell (TSA) hydrogel system induced significantly (p < 0.05) lower than the control group (MMC and TGFβ1) collagen type I deposition (assessed via SDS-PAGE and immunocytochemistry), α smooth muscle actin (αSMA) expression (assessed via immunocytochemistry) and cellular proliferation (assessed via DNA quantification) and viability (assessed via calcein AM and ethidium homodimer-I staining) after 10 d in culture. On the other hand, direct TSA-TGFβ supplementation induced the lowest (p < 0.05) collagen type I deposition, αSMA expression and cellular proliferation and viability after 10 d in culture. Our results illustrate the potential of core–shell collagen hydrogel systems for sustained delivery of antifibrotic molecules.
50
Chakravarty, Aranyak, Mahesh V. Panchagnula, Alladi Mohan, and Neelesh A. Patankar. "Pulmonary drug delivery and retention: A computational study to identify plausible parameters based on a coupled airway-mucus flow model." PLOS Computational Biology 18, no. 6 (June 2, 2022): e1010143. http://dx.doi.org/10.1371/journal.pcbi.1010143.
Full textAbstract:
Pulmonary drug delivery systems rely on inhalation of drug-laden aerosols produced from aerosol generators such as inhalers, nebulizers etc. On deposition, the drug molecules diffuse in the mucus layer and are also subjected to mucociliary advection which transports the drugs away from the initial deposition site. The availability of the drug at a particular region of the lung is, thus, determined by a balance between these two phenomena. A mathematical analysis of drug deposition and retention in the lungs is developed through a coupled mathematical model of aerosol transport in air as well as drug molecule transport in the mucus layer. The mathematical model is solved computationally to identify suitable conditions for the transport of drug-laden aerosols to the deep lungs. This study identifies the conditions conducive for delivering drugs to the deep lungs which is crucial for achieving systemic drug delivery. The effect of different parameters on drug retention is also characterized for various regions of the lungs, which is important in determining the availability of the inhaled drugs at a target location. Our analysis confirms that drug delivery efficacy remains highest for aerosols in the size range of 1-5 μm. Moreover, it is observed that amount of drugs deposited in the deep lung increases by a factor of 2 when the breathing time period is doubled, with respect to normal breathing, suggesting breath control as a means to increase the efficacy of drug delivery to the deep lung. A higher efficacy also reduces the drug load required to be inhaled to produce the same health effects and hence, can help in minimizing the side effects of a drug.